🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Stepan Company (SCL)
NYSE: SCL · Real-Time Price · USD
63.48
-1.52 (-2.34%)
At close: Nov 20, 2026, 4:00 PM EST
64.72
+1.24 (1.95%)
After-hours: Nov 20, 2026, 7:32 PM EST
← View all transcripts

18th Annual Southwest IDEAS Conference

Nov 19, 2026

Summary

YTD organic volume grew 4% across segments, while nine-month EBITDA rose 15% YoY to $190 million. Project Catalyst targets $100 million in two-year pre-tax savings, with $66 million-$70 million already achieved in 2026.

Operator

Up next, we have Stepan Company, traded on the NYSE under symbol SCL. On behalf of the company, we have Ruben Velasquez, Chief Financial Officer.

Ruben Velasquez
CFO, Stepan Company

Good afternoon. It is a pleasure to be here. Thank you very much for joining. Ruben Velasquez, Chief Financial Officer for Stepan Company. I mean, of course, I am not going to get into all of the details of the presentation and the slides that you got, but maybe I want to focus in some of the four things that maybe I want you to really take from this presentation regarding the Stepan story. The first is the quality and diversification of our portfolio, and I am going to elaborate a little bit on that. The second is the opportunities that we see for accelerated growth. The third is everything that we have been doing from a structural point of view regarding our operational excellence, that is Project Catalyst. Maybe some of you have heard about Project Catalyst.

All of that has translated into some good margin improvement and our ability to deleverage the balance sheet and to improve our cash and liquidity positions. Okay, so let us see. It is very difficult to present after a nice, good lunch like the one that we just had. They always say, "If you want to avoid people dozing off, you need to show a picture or a video." So here is the picture. Last week, we were at the NYSE in the ringing bell of the closing of the day. It was really exciting. There is the board of directors of Stepan and the executive committee of the company. We are actually celebrating our 30th year in the NYSE. Before that, we also traded in other stocks. We have been public for almost 60 years.

That was also the start of our 95th anniversary as a company. So we have been around quite a bit. But at the end, today is not about what we have done in the last 95 years. It is more about what is our Stepan story and how do we plan to continue to generate value for the years to come.

For those of you who are maybe not that familiar with the Stepan story, basically, we have three main lines of businesses: Surfactants, Polymers, and Specialty Products. And it is a diverse portfolio that goes into diverse segments. If we think of our Surfactants business, which is around 70% of our sales, the primary end markets of our Surfactants products are personal care, crop productivity, oilfield services, construction, and industrial. So, very diverse in terms of the end markets that we reach with our Surfactants portfolio.

In terms of Polymers, think of this is more insulation, so insulation panels for commercial construction, for residential construction. We also go into some of the CASE and powder resins. We have Specialty Products, that is another segment, smaller, but profitable, if you have seen the numbers, that goes into more of the food industries, nutraceuticals, pharmaceuticals. That's high level, the portfolio for Stepan. Okay, I don't know what I did here, but okay. Our footprint, yeah? We are a global company. We have 19 sites around the world in four continents. But actually, I would say that having regional supply is probably one of the biggest strengths of Stepan, yeah? We have historically developed around serving customers close to their facilities, yeah? Let's say in these days in which supply chain disruption is all over the place, yeah?

Nobody wants to be moving product from one continent to the other. This has been a major competitive advantage for Stepan. We do not have to move product. I mean, we are very close to our customers, so that has been a really, really good advantage. I only joined Stepan one and a half years ago, a little bit less. Before that, I worked 18 years for 3M Company. Before that, I worked in the oil and gas industry. While I worked for 3M, some of you may know 3M, it's a global company, 170 facilities around the world, five big businesses. One of the roles that I had there was CFO for manufacturing supply chain. I really don't know why they put me in that role. I was not expecting to do a lot of supply chain. I learned more than what I wanted, especially during the pandemic years.

But one of the biggest things that I learned in that role was, you've got to build flexible supply chains. It's not even about trying to get a 1% discount in a material. It's about being able to have flexibility, being able to be close to the customer, being able to pivot easily. That's some of the things that we are actually doing in Stepan, and I will comment a little bit on that. But bottom line, global scale, but regional strength. Okay, now getting a little bit more into which are our end markets. As I mentioned before, Surfactants business is around 70% of our sales. Polymers is around 25%, then the Specialties is around 5%. You can see what is the split of EBITDA on the top right.

But at the end, the message that I want to leave from this slide is more which are our end markets. One thing that you can see there is that most of those end markets that we target are really things that are permanent in nature. I mean, it's not like a trend. It's something that is here and is here to stay, yeah? When you think about crop productivity, it's food safety. When you think of oilfield chemicals or polyols, it's about energy conservation. So many of the end markets that we are targeting, and that's why we are able to grow GDP or GDP+ in these segments is precisely because these are mega trends are here that we believe will continue to grow in the coming years. Okay.

Let's talk a little bit about the. If I move from here, then you will not hear, so I will need to stay here in the podium. Let's talk a little bit about the strategy. At the end, of course, it's about total shareholder return. This is what we really want to maximize, and of course, this is what our shareholders and stakeholders want. But we see four main components of our strategy. First is customer-focused solution, and I will elaborate in each of these. Then it's diversification strategy, and this diversification is both from a customer perspective, from a product perspective, and from a channel perspective. Then operational excellence, and here I will elaborate into our Project Catalyst, that is the big initiative that we have as a self-help or cost-out initiative, and also in a way of transforming the company, particularly the manufacturing supply chain.

From a financial strength perspective, our goal continue to be to generate EBITDA, generate free cash flow conversion, increase our conversion, deleverage the balance sheet. We are already in a good position. I will show where we are in terms of net leverage, deleverage, but we are trending in the right direction. Let me focus a little bit on customer-focused solutions, because a lot of people in the different investor meetings, they ask me about this. And it's, I mean, chemical company, we invest in innovation, but we purposely invest on customer-focused innovation. What do we mean by this is, there are many companies who have a lot of R&D, a lot of innovation, they have a lot of scientists who love to develop products, but sometimes those products don't end in an application or don't end in a customer.

I mean, you can develop the best product in the world in terms of performance. If people don't buy it, if people don't need it, then that's wasted innovation. So, we have been purposely looking to work very close with customers, and this is connected to what I will explain later in terms of our tier 2 and tier 3 strategies. We have been growing and purposely focusing and investing capital on customers that want to develop an application together with Stepan. We have scientists, we have more than 230 people in the company between scientists and engineers, applications, and we develop solutions for customers together with them. Sometimes it's, maybe here in Texas, we are in the Houston lab, and we have a tier 2, tier 3 company that wants to develop a specific application for oil and gas, special recovery for Surfactants.

A lot of what we are doing in terms of growth is focusing on those customers that see Stepan's capability to develop products and to develop applications. Then the diversification strategy. Those of you who may have heard the Stepan story in the last 20, 50 years, Stepan is a company that grew around serving large consumer customers, the Procter & Gambles of the world, the Unilevers. And typically, we would develop a plant close to the customer and selling surfactants to those very large consumer customers. And this has worked very well. We have very, very important relationships with many of those large tier 1 customers in the consumer segments. But we also want to make sure that we develop other customers, other products, and this is our diversification strategy.

Yeah, if you look at where Stepan has been growing the most in the last few years, it is with what we call priority segments. Priority segments is basically what we call functional, that is, oilfield services, crop productivity, some of the Polymers business in construction. Then moving into customers, which are maybe smaller than the larger ones, with less capabilities to develop innovation, and those are the ones that we have been focusing. These are, of course, customers where we have better margins, because we use our innovation with them, and they depend more on us. A lot of what we have been doing lately is making sure that we secure volumes, and a lot of the volumes that we have in the company are coming from those big consumer and end consumer customers, like the Procter & Gambles of the world.

Those are the ones that keep our plants full. Those are the ones that bring the volume. At the same time, a lot of our profit at EBITDA is coming from these other smaller segments with customers where we have a lot better margins given that we are applying our innovation there. Then operational excellence, then maybe I am going to move a little bit here before I forget. So diversified growth. This is important because a lot of people ask me as well, "Well, Ruben, how is it that you are growing 6%, 7% in an industry that nobody is growing?" I mean, it is not a secret that chemical industry is not the fastest growing segments. We have been able to grow consistently this year with a 4% organic volume in the last couple of quarters, 6%, 7%.

This is not growth that is coming just from one place, one product, or one region. It is widespread, it is in most regions, it is in all of our global segments, Surfactants, Polymers, and Specialty Products. Then it is going basically into these segments that you see there, crop productivity, oilfield solutions, and rigid polyols. The reason why we are able to grow faster in many of those segments is because we have relatively small market share. Crop productivity is less than 7% market share. Oilfield solutions is less than 2%. So let us say we have a lot of room to grow in these segments, and that is the reason basically why we have been able to post faster growth compared to many of our peers.

From an EBITDA generation perspective, it is important that you see maybe the bottom left of this chart, because it comes back to the story of which businesses are generating volume, which businesses are generating margins. What we call priority segments that are in the top section of this slide, those priority segments are 40% of our volume but represent almost 80% of our EBITDA. So, we really have a really good combination today in the company between large customers that bring a significant volume that keep our facilities full, our plants full, together with faster-growing segments where we are generating more EBITDA margin and margin expansion. Okay, I am not going to stop a lot here on each of these slides. I just want you to see, for example, in this case of Surfactants, you can look at the market shares, so what I was mentioning before.

In many of these cases, we have a lot of opportunity to penetrate some of these segments, and are segments that are not necessarily growing double digits, but the fact that we have lower market shares, this helps a lot, right? I mean, developing oil and gas, once you develop an oil and gas application with a tier 2, tier 3 customer, or maybe with a national oil company in which we put our surfactants into their chemistry, then those are sales that are sticky sales. Those are sales in which our customers like the innovation and like the fact that we develop with them a solution, and those sales tend to be very sticky and, of course, coming with better margins again. Similar with Polymers.

Polymers, for those of you who are not familiar, this is basically going into construction segments, so insulation panels for commercial buildings, also insulation for residential, which is probably the spray foam. Stepan traditionally has been playing much more on the industrial side, on the commercial building side. This is our polyiso, many products that practically Stepan invented. This is a place where we have 60% market share. But we also have residential now, right? It is a spray foam. Again, it is not like a spray foam is a new product. Spray foam has been there in the market already for a lot, but this was not a segment where Stepan was playing aggressively in the past. Now we are doing that. We have a very low market share, 2%, growing fast.

That what we have been saying in the last calls, it is like double-digit growth already for the last few quarters. We are also capturing those segments in which maybe we were not present before, and this is also contributing a lot to the good growth that we have been having in the last few quarters. Operational excellence, and I think that this is a key one, because I want you to think of Stepan not only as a volume growth story. I mean, of course, 4% organic volume growth throughout this year is fantastic. Many people say, "Wow, can you keep that?" Of course, we want to keep a healthy growth, but at the end, we do not want to depend just in our growth story. We want to depend a lot also on things that we can control.

This is basically our operational excellence initiative, which is more related to what probably some of you may have heard about Project Catalyst. Let me stop here a little bit because this is an important piece. This is basically our self-help story. It is not only about cost out. In a way, it is the approach on how we are managing the company now from a transformational perspective. A lot of the good performance that you have seen year to date this year in the case of Stepan, which 15% EBITDA growth for the year, so not bad, right? 15% EBITDA growth is not only the volume growth. It is a lot of what we are doing here in operational excellence, and it is this Project Catalyst. Basically, Project Catalyst is an initiative in which we are targeting $100 million in pre-tax savings during two years.

I mean, think of a company like Stepan, $1.4 billion-$1.5 billion of market cap with a $100 million initiative. It is big. It is massive. It has three main components. It is about rationalization of footprint. It is about the right organizational design, not necessarily restructuring, but the right organizational design. Then the third is operational efficiencies and cost optimization, which I would say this is more similar to what many companies in the chemical industry have in terms of waste reduction of non-conformities, reduction of shrink, and all those story. We have not publicly said how much of the $100 million is each of these categories, but what I can tell you is, I mean, footprint is a big part of it. Then footprint is really about consolidating volume into new, more efficient facilities. We are in Texas.

We are very proud that last year we launched our large alkoxylation facility in Pasadena. We invested hundreds of millions of dollars in that facility, which is very efficient. So, we were really able to consolidate many volumes, particularly here in the U.S., many of the volumes that we had in other facilities in the East Coast and in Illinois into this Texas facility that has been ramping up significantly in a very good way. We are around 80% utilization now for this Pasadena site. By the way, we ended up, I mean, we shut down one of the largest facilities that Stepan had for many years in New Jersey. So basically, it is reallocation of volumes into faster, more efficient facilities. That has been a key component.

The good thing is that of this $100 million, again, most of it is footprint, and already in 2026, we said this publicly, we are already achieving $66 million-$70 million of those $100 million. That is already there. I mean, it is not a promise for two years. It already happened. Already our Q3 results, we mentioned this publicly, are having a run rate of savings of around $23 million per quarter for these actions. This was related to facilities that we shut down, so of course, less depreciation of assets, less operational expenses. So that is a lot of our 15% EBITDA growth this year, and that will extend into next year because we said it is a two-year program, $100 million, of which $66 million-$70 million is in 2026. So, you can do the math.

There is quite a bit of carry forward into 2027. So, we feel very confident and know that our future is good in this sense. I mean, a lot of this is going to be savings that we are already counting on because they are real. From an organizational effectiveness perspective, I have done so many restructurings in my life in different businesses, in different companies, and I hate when we think of restructuring as just cost out, take people out. What we did in Stepan was right-sizing the organization. It was making sure that we had the right people in the right positions. It was a talent redesign. In some cases, we brought new people to the company. People that we know that is going to help us to do the transformation. So this is not just about eliminating 100 roles.

That was the net result of thinking of what is the right structure that the company needs and what is the way in which we want to manage the talent. This is Project Catalyst. I know a lot of people ask me about Project Catalyst in our different investor meetings, in our different investor call. I say as a takeaway here is, this is real, it's already happening, it's the self-help story, it's not a promise, it's here and it's now. Okay. Supply chain. I cannot say much more about this, but I insist on the importance of having a flexible supply chain. The fact that we have regional assets in different continents helped us significantly to manage all this disruption with the freight and products moving around the world, and the lack of raw materials, lack of availability.

It has helped us significantly, and I would say this is one of the significant competitive advantages that Stepan has, that is, our supply chain is regional. It's global in a sense, but it's regional, as we have regional sales or supply, and this has helped us significantly to be able to supply our customers in regions where sometimes for others or our peers, it's difficult given the configuration of their supply chains. Okay. Then, of course, I need to move into our financial priorities, yeah? Yes, we have been, of course, generating quite a bit of EBITDA in the last few quarters. We have said this publicly. I mean, our strategy is, of course, to increase our EBITDA generation, increase our cash from operations, deleverage our balance sheet, and this is what we have been doing, making sure that we have a net leverage.

Right now, it's around 2.4, moving down from 2.7, our net leverage ratio, so it's improving. For chemical industry standards, I believe it's in a really good place. But we want to continue with this trend of deleveraging the balance sheet. Yeah, we want to be in a position that if we need to come back to an intensive capital investment stage, then we have the ability to do that, and that's why, let's say, for now, our strategy will continue to be generating EBITDA, generating cash, paying down debt, deleveraging the balance sheet. Okay, so let me see. 13 minutes, still good. Just a little bit on our Q3 year-to-date performance, so performance on September year-to-date. As I mentioned, we have been able to post good results. EBITDA for the first nine months of the year, $190 million, which is 15% growth year-on-year.

As I mentioned before, this is not only a growth story, it's also a self-help story. From a volume growth perspective, that 4% of organic volume growth year-to-date, it's coming from all of our business segments. I want to insist on that because I get a lot of people asking me, "Well, is it just one region? Is it just Surfactants? Did you have one large customer who got crazy, wanted to secure supply?" The answer is no. This is broad-based growth. It's in all of our global segments, yeah? In most of our regions. If you ask me, "Okay, so where is the softest spot?" Yeah, Polymers in Europe. I mean, construction in Europe is not growing anywhere, yeah?

We feel very well with the portfolio that we have in Europe in our Polymers business, but the reality in Europe is that it's a market that is not growing that much. It's not growing as it is growing, for example, in the U.S., where there is a lot of commercial construction. Europe is a market that has been kind of stagnant in the last few years. Of course, interest rates play a big role on this. I mean, nobody wants to invest in construction with the level of the interest rates right now. At the same time, those of you who are familiar with Europe, I mean, the amount of additional regulation in terms of energy conservation, the amount of regulation for chemical industries.

I mean, at some point, there is going to need to be a re-roofing of the buildings and the residences and the houses in Europe, right? I mean, you can postpone a little bit, like investing in re-roofing and insulation, but at some point, even if interest rates are high, you will need to do it, right? Moreover, as now, like you have seen maybe electricity prices, gas prices in Europe are unmanageable for most companies. So, at some point, they're going to say, "Well, I need to insulate my building better so that I don't pay so much in utilities." We love the portfolio that we have in Europe. We have a very strong position in Europe in our Polymers business, and we are super ready for the next cycle of construction in Europe. That's the good thing, right?

We have the facilities there, we have the infrastructure there. It's not like whenever the wave comes, then we need to build it. No, we are ready to take advantage of that next cycle. And then the organic volume growth, 4% year-on-year. Again, as I mentioned, it's broad-based. Now within that, a lot is coming from this tier 2, tier 3, smaller to medium customers that I mentioned before. Yeah. Customers where we provide a lot of innovation, customers that really want to partner with Stepan to develop an application, and a lot of the growth has been coming from a Surfactants perspective. On the Polymers side, North America, what we call the rigid building, that is the rigid business that is basically insulation for commercial buildings.

Here in the U.S., that has been a business that, I mean, it's not growing double digits, but it has been growing low single digits, so it's stable. It's a good business for us. And then spray foam. You have seen, I mean, we have said this in the different earnings call. I mean, we have been having double-digit growth for spray foam for the last few quarters, and that is helping a lot. Project Catalyst, as mentioned, is already a big piece of why we are seeing good results this year in our margins, margin expansion, a lot coming from that Project Catalyst. Also, as mentioned before, 60% of that is in 2026, 40% of that is in 2027, and the actions are already performed. So let's say it's savings that we know that will be coming.

Safety, of course, as any chemical company, that continues to be a priority. It is part of our DNA, it is part of everybody's responsibility to make sure that we operate safely. Here is a place where there are no excuses. You cannot take your eyes out of safety, and that will continue to be a priority for the company. I think, given that we have only eight minutes left, I would like maybe to open it to questions, if you may have. Maybe you want me to elaborate a bit more in any other things related to our growth strategy, related to our portfolio, related to our cash position. So, questions?

Speaker 3

Can you talk about customer concentration? Do you have any specific customer concentration?

Ruben Velasquez
CFO, Stepan Company

By customer concentration, you mean like in type of customers or

Speaker 3

More than 10% in one customer, do you have to disclose?

Ruben Velasquez
CFO, Stepan Company

Oh, I got it. I would not say that it is a critical thing for Stepan. We have reduced a lot the customer dependency that maybe we had in the past with some of these large consumer customers, in which basically Stepan was serving a lot of large customers, the Procter & Gambles, the Syngentas, these large companies. With our diversification strategy of growing more with tier 2 and tier 3 customers, that dependency has reduced. It is part of what we want to do. We do not want to be that exposed to just one single customer. Also because at the end, these large customers that go into the consumer segments, these are large customers that have the ability to backward integrate any moment.

But at the end, as I mentioned, tier 1 customers in the consumer segments, these are legacy relationships that Stepan has had with this customer with so many years. I do not want to speak for the customers, but I am sure that if you talk to them, they are going to say, "Stepan is a company that we rely on. Stepan has been serving us for 70, 80 years." Every time that these companies develop a new product or a new formulation, we are there. I do not want to brag, but that is the reality. We have been able to be in their different product formulations, the different product presentations, like for many, many years. The other thing is that many people ask me also in the investor's presentation, "Do not you get a ton of pressure from these companies to reduce?

They want to squeeze all of the suppliers." Of course, every company does. We do it as well, right? But at the end, remember that the surfactant at the end is the cleaning component, right? The surfactant in the cost structure of our customers, especially in these big consumer customers, is not necessarily a big component of the total cost of the product, but the surfactant can make a big problem with the performance of the product. So, if you get your surfactant messed up or not the right formulation, then the whole performance of the product is going to be compromised. These companies for many years did what we call deformulations, right? So, they were basically reducing the amount of surfactant and increasing the amount of water.

Every time that you would buy a shampoo or a laundry cleaning, whatever, it will be more water, less surfactant. There is a point in which if they continue to reduce the surfactant amount, the product is not going to clean, right? I think that in a way, they have reached a little bit of that threshold. Probably you have heard for the first time in many years, companies like Procter & Gamble are saying, "We are going to provide product with better performance for the same price." First time ever that they say, "It looks like I need to come back to improve the performance of my product." So, it is not that I am saying that we are not exposed to more deformulations on the Surfactant side, but the point is, you need a cleaning agent.

You cannot continue to take surfactants out of the product in the way that maybe they did in the past. Let's say in a way, again, I don't want to give the impression that we don't like or that we don't depend on our large consumer customers. They are still the core of our company. They are still, again, the customers that keep our facilities full, our tanks full, and we love them. But I really like the fact that we are able to have volume from tier 1 customers and being able to generate margin from other customers in which we can provide more innovation and more service. Any other questions? Come on, I know it's lunch. I know it's

Speaker 3

Can you just explain how does this surfactant increase crop productivity?

Ruben Velasquez
CFO, Stepan Company

Yeah, absolutely. Thanks for that question. Basically, in simple words, it helps to increase the productivity of a plantation.

Speaker 3

Is it like a fertilizer?

Ruben Velasquez
CFO, Stepan Company

It is actually applied at the end of the cycle with the pesticide, yeah? If you think of a grower, of somebody who is in the agricultural business, right? There is a share of wallet that they have. Initially, they need to apply the right amount and quantity of fertilizers to try to make sure that, yeah. Then, depending on the weather, they need to apply more or less pesticides to make sure that, yeah. A lot of what we do in our surfactants is that combination. I mean, let's say, advising the grower on how much should be the amount of pesticides versus fertilizers versus a surfactant. Because depending on that combination that goes into something that is called a tank mix adjuvant, then the productivity of a plantation could grow up to 20%, yeah?

This is important because many people also ask us, "Well, but with El Niño, then ag is going to suffer, fertilizers are up. Is your business going to be suffering?" And the reality is that, yeah, I mean, of course, in a sense that, if fertilizer prices go up too much, well, for a grower, they have typically a fixed wallet. So , if they need to invest too much in the first phases, that is the fertilization, then they may not have enough money for the other piece that is pesticides and surfactants and all the other needs. At the same time, right, if you can show a grower that by applying the right amount and the right combination of surfactants and pesticides, you can increase the productivity of a plantation by 15%, then they are going to invest in the surfactant, yeah?

Now, one thing about ag, because this is also something that many people ask me is like, "How much is your sales?" Or "Are you serving just small growers or are you also serving large customers?" And the answer is, we serve both, yeah. Syngenta is one of our largest customers in ag, and this is a tier 1 huge customer in which, of course, probably they buy more of the commodity surfactants into their formulations. At the same time, we serve tier 2, tier 3, smaller companies in ag, which depend more again on Stepan's innovation. Those are different channels. It's a different cost to serve. Of course, it's not the same serving Syngenta than serving a grower in the middle of Brazil. So, we have different business models to serve those customers. But again, we have seen that we want large customers with good volume.

We also love smaller customers in which we can put our innovation, develop applications, and of course, get better margins with those customers.

Speaker 3

Thank you.

Ruben Velasquez
CFO, Stepan Company

Thank you. Yeah.

Speaker 3

Talk a little bit about market share growth and growing with tier 2 and tier 3. It seems like maybe you get better pricing from them, but you do not get the uplift from utilization at facilities from an OpEx perspective. How do you balance that?

Ruben Velasquez
CFO, Stepan Company

It is a great question. That is exactly how we can balance it. Again, we want to secure the volumes from the large tier 1s, tier 2. It is not that we do not care for the volumes of the tier 2 and tier 3, but we know that with tier 2, tier 3, the real investment is on the application development side. That is what I was saying, the cost to serve those two channels is completely different. So far, we have that benefit that we have enough volume from tier 1 customers, and then faster growing tier 2, tier 3. With tier 2, tier 3, we monitor two things. First is how many new customers in those segments we have, but it is also how much additional products do we sell to each of those customers.

You have heard us in some of the calls saying, "Yeah, we increased our customer product combinations by 800 in Q3." Meaning it is not only the amount of customers, it is how much do we sell to each of those customers. With tier 2, tier 3 customers, we have been able also to grow the amount of products, I mean, Stepan product that we sell into them. It actually is also a good source for volume, but again, with them, the priority is more the margin management than the volume. Okay, I think that my time is over. Thank you so much for your attention. Really appreciate it. Thank you.